is saxenda a glp 1 drug Article » ProAct Obesity drug cuts opiate craving
Description
doi: 10.1007/s13300-019-00735-7
Treatment with exenatide increased insulin signaling pathway activity, AMPK signaling pathway activation, and lipid oxidation enzyme stimulation [73]
All company claims are attributed to the brand and clearly distinguished from independent research findings
doi: 10.1210/clinem/dgad361
Cardiovascular benefits have been demonstrated in clinical trials, with specific agents showing reductions in major adverse cardiovascular events
